Incannex Receives Ethics Approval For Bioequivalence/Bioavailability Clinical Trial For IHL-42X, The Co's Proprietary Drug For Treatment Of Obstructive Sleep Apnoea
Portfolio Pulse from Happy Mohamed
Incannex Healthcare Limited (NASDAQ:IXHL) has received approval from Bellberry Human Research Ethics Committee to commence a bioavailability/bioequivalence clinical trial on IHL-42X, its proprietary drug for treatment of obstructive sleep apnoea. The trial will include 116 participants and will be managed by Novotech. The results will be a critical component of future marketing submissions for IHL-42X. The trial will run in parallel to the pivotal Phase 2/3 trial.
July 06, 2023 | 12:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Incannex's approval to commence a clinical trial for its proprietary drug IHL-42X could potentially boost its stock as it signifies progress in the company's drug development pipeline.
The approval to commence a clinical trial for IHL-42X is a significant milestone for Incannex. It signifies progress in the company's drug development pipeline, which could potentially attract investors and boost its stock. However, the actual impact will depend on the results of the trial and the market's perception of its potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100